ORIGINAL ARTICLE

Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China

Xin Zheng,1 Rachel P Dreyer,2 Shuang Hu,1 Erica S Spatz,2,3 Frederick A Masoudi,4,5 John A Spertus,6 Khurram Nasir,7 Xi Li,1 Jing Li,1 Sisi Wang,2,8 Harlan M Krumholz,2,3,9,10 Lixin Jiang,1 for the China PEACE Collaborative Group

ABSTRACT

Objective To assess whether younger, but not older, women in China have higher in-hospital mortality following ST-Segment Elevation Myocardial Infarction (STEMI) compared with men, and whether this relationship varied over the last decade or across rural/urban areas.

Methods We analysed a nationally representative sample of 11,986 patients with STEMI from 162 Chinese hospitals in 2001, 2006 and 2011 in the China PEACE-Retrospective AMI Study and compared in-hospital mortality between women and men with gender–age interactions in multivariable models.

Results The overall in-hospital mortality rate was higher in women compared with men (17.2% vs 9.1%, p<0.0001; unadjusted OR 2.07, 95% CI 1.85 to 2.33). The unadjusted OR for mortality in women, compared with men, was 2.20 (95% CI 1.59 to 3.04), 2.21 (95% CI 1.74 to 2.79), 1.37 (95% CI 1.15 to 1.65) and 1.25 (95% CI 0.97 to 1.63) for ages <60, 60–69, 70–79 and ≥80 years, respectively. After adjustment for patient characteristics, hospital characteristics and year of study, the OR for mortality comparing women with men was 1.69 (95% CI 1.01 to 2.83), 1.64 (95% CI 1.24 to 2.19), 1.15 (95% CI 0.90 to 1.46) and 0.82 (95% CI 0.60 to 1.11) for ages <60, 60–69, 70–79 and ≥80 years, respectively. The gender–age interaction for mortality was statistically significant (p=0.009), even after adjustment for a wide range of confounders, and did not vary over time or across rural/urban areas.

Conclusions Among a Chinese population with STEMI, gender differences in early mortality were age-dependent and greatest in the younger groups <70 years of age.

Trial registration number http://www.clinicaltrials.gov (NCT01624883).

INTRODUCTION

Several studies from high-income areas, including the USA, Canada and Europe, have demonstrated gender differences in mortality following acute myocardial infarction (AMI) that vary by age,1–8 with a higher risk of death in younger women compared with their male counterparts. For example, in a US study of patients hospitalised with AMI between 1994 and 1998, women aged ≤50 years had a more than twofold greater in-hospital mortality compared with similarly aged men,4 but this difference was not present in older patients. A remaining question is whether this gender–age interaction in AMI mortality, in which gender differences are greater in younger patients, exists in diverse populations and healthcare systems, especially in low-income and middle-income countries.

In China, home to one-fifth of the world’s women, there is a rising burden of cardiovascular disease.9 Moreover, as observed in the recently published China Patient-centered Evaluative Assessment of Cardiac Events (China PEACE)- Retrospective AMI Study of patients with ST-Segment Elevation Myocardial Infarction (STEMI), there was a fourfold increase in hospital admissions among both men and women over the last decade, with women persistently accounting for nearly 30% of all patients.10 In this growing population of women with AMI, it is critical to understand whether gender differences in survival among different age groups exist, especially as China prepares to embark on national efforts to improve the quality of AMI care.

Examining potential gender disparities in STEMI outcomes in China is important, as findings from Western countries may not be broadly applicable. Though prior studies from China have suggested higher rates of death in younger women after STEMI,11 these data are not contemporary and may not reflect the experience of average patients as they were based on clinical trial populations. Further investigation is needed to understand whether age–gender disparities exist among a nationally representative sample and whether differences in outcomes have changed over the last decade. Additionally, to inform future interventions, it is important to understand whether any differences observed can be explained by patient risk, hospital care management or the settings in which care is delivered.

Accordingly, we examined a nationally representative sample of patients with STEMI in the China PEACE-Retrospective AMI Study in 2001, 2006 and 2011. The objectives of this study were to (a) assess whether there is a significant gender–age interaction with in-hospital mortality among Chinese patients with STEMI; (b) identify factors that may explain this gender–age interaction and (c) determine whether this gender–age interaction has changed over time or varies across rural/urban areas. We hypothesised that younger, but not older,
women with STEMI in China would have a higher risk of in-hospital mortality, compared with age-matched men. The findings of this study will assist in identifying vulnerable groups at risk for early mortality, identifying potential mediators of mortality differences, and stimulating quality improvement efforts to improve outcomes for younger women with STEMI.

METHODS
Data source and study population
The design of the China PEACE-Retrospective AMI Study has been previously described. In brief, we created a nationally representative sample of hospitalisations for AMI during 2001, 2006 and 2011 using a 2-stage random sampling design. Since hospital volumes and clinical capacities differ between urban and rural areas, as well as among the 3 official economic-geographic regions of China, we identified hospitals in 5 strata: Eastern-rural, Central-rural, Western-rural, Eastern-urban and Central/Western-urban regions. We then used systematic random sampling to sample cases with AMI, which were identified using International Classification of Diseases versions 9 and 10, when available, or through principle discharge diagnosis terms from the selected hospitals.

We included patients with STEMI (n=13 815), which was confirmed by discharge diagnosis and electrocardiogram results. For the purposes of the present analysis, patients who were transferred in (n=559), transferred out (n=1148) or discharged within 24 h of admission (n=122) were excluded. The final study cohort consisted of 11 986 patients (n=3574 women, 29.8%).

The Chinese government, which provided financial support for the study, had no role in the design or conduct of the study; in the collection, management, analysis and interpretation of the data; or in the preparation or approval of the manuscript. The central ethics committee of the China National Center for Cardiovascular Diseases approved this study. All collaborating hospitals accepted the central ethics approval except for 5 hospitals that obtained local approval by internal ethics committees. The study is registered at http://www.clinicaltrials.gov (NCT01624883).

Medical record review and variables
Data were collected via standardised central medical chart abstraction using standardised data definitions. Variables abstracted from the medical records of each hospital included patient-level characteristics, hospital-level characteristics, year of discharge. The in-hospital mortality was defined as a composite of death during hospitalisation or withdrawal from treatment due to a terminal status at discharge. Withdrawal from treatment is common in China due to many patients’/families’ reluctance to die in the hospital. The Chinese government uses in-hospital death or withdrawal from treatment as an indicator of quality for hospitals. Composite complications included re-infarction, cardiogenic shock, cardiac arrest, congestive heart failure, and ischaemic stroke (for definitions, see online supplementary appendix).

Major bleeding included any intracranial bleeding; or absolute drop of haemoglobin of at least 5 g/dL; or bleeding resulting in hypovolemic shock or fatal bleeding (bleeding that directly results in death within 7 days).

Statistical analysis
Based on the distribution of in-hospital mortality among women and men, as well as the cut-off of age used in a previous landmark manuscript, we stratified the study sample into 4 pre-specified age groups (<60, 60–69, 70–79, and ≥80 years). Continuous variables were expressed as mean±SD and compared using unpaired t test. Using χ² tests, we compared cardiovascular risk factors, medical history, clinical characteristics at admission, treatment during hospitalisation, in-hospital outcomes, hospital characteristics, and year of discharge between women and men in each age group. Crude ORs with 95% CIs for women versus men were reported.

We used multivariable logistic regression models to calculate adjusted OR and 95% CI for in-hospital mortality in the overall population and within each age group, and to determine whether there was a significant interaction between gender and age with respect to in-hospital mortality. Candidate variables for inclusion in the multivariable models included cardiovascular risk factors, medical history, clinical characteristics at admission, treatment during hospitalisation, length of stay, hospital characteristics, and year of discharge. The final models included only those variables that differed significantly between women and men (p<0.05). We also assessed 2 three-way interaction terms: (1) gender×age×year and (2) gender×age×rural/urban to assess whether age-dependent gender differences in in-hospital mortality changed either (a) over time or (b) across rural/urban areas. All comparisons were 2-tailed, with a p value<0.05 considered statistically significant. Statistical analyses were performed using SAS software (V9.2, SAS Institute, Cary, North Carolina, USA) and R software (V3.0.2).

RESULTS
Baseline characteristics
Women presenting with STEMI were significantly older than men with STEMI (69.8±10.4 years vs 62.6±12.6 years, respectively, p<0.001). Younger women (<60 years) were more likely to have hypertension (OR=1.84; 95% CI 1.54 to 2.20), diabetes (OR=2.06; 95% CI 1.68 to 2.54) and were less likely to smoke (OR=0.09; 95% CI 0.07 to 0.12) compared with men. Women over the age of 60 years were also less likely to have had a prior AMI. Differences in these cardiovascular risk factors were attenuated in the older age groups (table 1).

Clinical characteristics at presentation also differed between women and men with significant variations by age group. Younger women (<60 years) were more likely than similarly aged men to have symptoms lasting >24 h before hospital admission, while older women (aged 60–69 and 70–79 years) were less likely to have experienced chest discomfort compared with men. Younger women (<60 years) had higher systolic blood pressures and higher heart rates (≥100 bpm), but fewer cardiac arrests at presentation compared with similarly aged men and with older women. Additionally, younger women had worse renal function (glomerular filtration rate <60 mL/min) and higher low-density lipoprotein cholesterol levels than their male peers at presentation. Of note, women <60 years of age were more likely to live in rural than in urban areas (table 1).

In-hospital treatments also varied by gender and age. Younger women (<60 years) were less likely to receive clopidogrel within 24 h of admission (OR=0.80; 95% CI 0.67 to 0.93) or any statin therapy during hospitalisation (OR=0.79; 95% CI 0.65 to 0.96). Women aged 60–69 years were also less likely to receive aspirin, clopidogrel and β-blockers within 24 h of admission and statins during hospitalisation. With respect to reperfusion strategies, women aged <80 years were less likely to receive any reperfusion, especially those <60 years (OR=0.68; 95% CI 0.56 to 0.81), including less primary percutaneous coronary intervention (PCI) within 24 h (OR=0.54; 95% CI 0.40 to 0.73), compared with similarly aged men. All
women were less likely to undergo cardiac catheterisation and those 60–69 and 70–79 years of age were less likely to undergo PCI or any revascularisation compared with their male peers (table 2).

Finally, women <60 years of age had higher rates of any composite complications than men, while there were no significant gender differences among other age groups. The rate of major bleeding was similar by gender in each age group (table 2).
The overall in-hospital mortality rate was higher in women than in men (17.2% vs 9.1%, p<0.0001; unadjusted OR 2.07, 95% CI 1.85 to 2.33). In-hospital mortality following STEMI increased with age for both genders. Among younger women (<60 years), the in-hospital mortality rate was twofold higher compared with men (9.4% vs 4.5%, p<0.0001; unadjusted OR=2.20, 95% CI 1.59 to 3.04), and similarly for women aged 60–69 years (15.2% vs 7.5%, p<0.0001; unadjusted OR=2.21, 95% CI 1.74 to 2.79). A higher risk of death was also observed among older women 70–79 years of age (18.6% vs 14.3%, p=0.0006; unadjusted OR=1.37, 95% CI 1.15 to 1.65), but there was no difference in the risk of death in women over 80 years of age (24.8% vs 20.8%, p=0.09; unadjusted OR=1.25, 95% CI 0.97 to 1.63). When mortality rates were examined by age, a gender–age interaction was observed (p=0.0007) (figure 1). In addition, we also found that women aged 60–69, as well as ≥80 years of age, were more likely to die within 24 h of admission compared with their male peers (table 2).

The gender–age–year interaction was not significant (p=0.38), indicating that the gender–age interaction did not change over time (figure 2). In addition, there was no gender–age–area (rural/urban) interaction (p=0.95), suggesting equally poor outcomes in women regardless of whether they were treated in urban or in rural hospitals.

### Table 2 Unadjusted OR for treatments, testing and in-hospital outcomes comparing women with men according to age

<table>
<thead>
<tr>
<th></th>
<th>Women (n=3574)</th>
<th>Men (n=8412)</th>
<th>Age group, year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Per cent</td>
<td></td>
<td>&lt;60 (n=3914) OR*</td>
</tr>
<tr>
<td>Acute medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin ≤24 h</td>
<td>83.9</td>
<td>87.5</td>
<td>0.83</td>
</tr>
<tr>
<td>Clopidogrel ≤24 h</td>
<td>51.5</td>
<td>56.6</td>
<td>0.80†</td>
</tr>
<tr>
<td>β-Blocker ≤24 h</td>
<td>43.8</td>
<td>48.5</td>
<td>0.87</td>
</tr>
<tr>
<td>ACE-I/ARB†</td>
<td>60.2</td>
<td>63.8</td>
<td>0.90</td>
</tr>
<tr>
<td>Statin</td>
<td>73.0</td>
<td>75.2</td>
<td>0.79†</td>
</tr>
<tr>
<td>Reperfusion therapies ≤24 h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary PCI</td>
<td>8.5</td>
<td>12.8</td>
<td>0.54†</td>
</tr>
<tr>
<td>Fibrinolytic therapy</td>
<td>18.9</td>
<td>24.7</td>
<td>0.88</td>
</tr>
<tr>
<td>Any reperfusion</td>
<td>27.4</td>
<td>37.5</td>
<td>0.68†</td>
</tr>
<tr>
<td>Staged procedures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac catheterisation</td>
<td>18.8</td>
<td>28.8</td>
<td>0.72†</td>
</tr>
<tr>
<td>PCI</td>
<td>8.6</td>
<td>13.9</td>
<td>0.84</td>
</tr>
<tr>
<td>CABG</td>
<td>0.34</td>
<td>0.61</td>
<td>0.58</td>
</tr>
<tr>
<td>Any revascularisation</td>
<td>8.9</td>
<td>14.4</td>
<td>0.84</td>
</tr>
<tr>
<td>Testing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troponin</td>
<td>48.9</td>
<td>49.9</td>
<td>0.85</td>
</tr>
<tr>
<td>Echocardiogram</td>
<td>46.1</td>
<td>52.6</td>
<td>0.97</td>
</tr>
<tr>
<td>In-hospital outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death†</td>
<td>12.5</td>
<td>6.7</td>
<td>2.29†</td>
</tr>
<tr>
<td>Death† + withdrawal from treatment</td>
<td>17.2</td>
<td>9.1</td>
<td>2.20†</td>
</tr>
<tr>
<td>Death within 24 h</td>
<td>5.5</td>
<td>2.9</td>
<td>1.75</td>
</tr>
<tr>
<td>Composite complications</td>
<td>15.3</td>
<td>11.8</td>
<td>1.46†</td>
</tr>
<tr>
<td>Major bleeding</td>
<td>0.8</td>
<td>1.0</td>
<td>0.22</td>
</tr>
<tr>
<td>Length of stay (days)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;8</td>
<td>29.5</td>
<td>22.7</td>
<td>1.03</td>
</tr>
<tr>
<td>8–11</td>
<td>20.9</td>
<td>24.0</td>
<td>1.35†</td>
</tr>
<tr>
<td>12–15</td>
<td>21.4</td>
<td>23.4</td>
<td>1.22†</td>
</tr>
<tr>
<td>≥16</td>
<td>28.2</td>
<td>29.8</td>
<td>1.60†</td>
</tr>
</tbody>
</table>

*The OR is for the comparison of women with men.†The OR is significant between women and men.‡During hospitalisation.

ACE-I/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; Composite complication: recurrent MI, cardiac shock, cardiac arrest, congestive heart failure and ischaemic stroke; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.

Unadjusted in-hospital mortality

The overall in-hospital mortality rate was higher in women than in men (17.2% vs 9.1%, p<0.0001; unadjusted OR 2.07, 95% CI 1.85 to 2.33). In-hospital mortality following STEMI increased with age for both genders. Among younger women (<60 years), the in-hospital mortality rate was twofold higher compared with men (9.4% vs 4.5%, p<0.0001; unadjusted OR=2.20, 95% CI 1.59 to 3.04), and similarly for women aged 60–69 years (15.2% vs 7.5%, p<0.0001; unadjusted OR=2.21, 95% CI 1.74 to 2.79). A higher risk of death was also observed among older women 70–79 years of age (18.6% vs 14.3%, p=0.0006; unadjusted OR=1.37, 95% CI 1.15 to 1.65), but there was no difference in the risk of death in women over 80 years of age (24.8% vs 20.8%, p=0.09; unadjusted OR=1.25, 95% CI 0.97 to 1.63). When mortality rates were examined by age, a gender–age interaction was observed (p=0.0007) (figure 1). In addition, we also found that women aged 60–69, as well as ≥80 years of age, were more likely to die within 24 h of admission compared with their male peers (table 2).

The gender–age–year interaction was not significant (p=0.38), indicating that the gender–age interaction did not change over time (figure 2). In addition, there was no gender–age–area (rural/urban) interaction (p=0.95), suggesting equally poor outcomes in women regardless of whether they were treated in urban or in rural hospitals.
Multivariable-adjusted in-hospital mortality

In the multivariable model, even after adjustment for differences in patient characteristics, hospital characteristics, length of stay and year of discharge, the interaction between gender and age for in-hospital mortality remained significant (p=0.0012). The adjusted OR for in-hospital mortality, comparing women with men, was 1.69 (95% CI 1.01 to 2.83), 1.64 (95% CI 1.24 to 2.19), 1.15 (95% CI 0.90 to 1.46) and 0.82 (95% CI 0.60 to 1.11) for age <60 years, age 60–69, age 70–79 and age ≥80 years, respectively. Women <70 years of age had an excess risk of mortality as compared with men; while there was no significant gender difference among patients ≥70 years old (figure 3).

DISCUSSION

In this first study to investigate gender differences in in-hospital mortality across the spectrum of age in a nationally representative population of patients with STEMI in China, women younger than 70 years had a >60% increased odds of dying in the hospital, compared with similarly aged men. This pattern of mortality was observed after accounting for differences in a wide range of patient and hospital characteristics. These mortality differences persisted despite changes in cardiovascular epidemiology over the last decade and differences in healthcare resources across rural and urban settings.

Our findings extend the previous literature, primarily based on US patients, by showing significant gender differences in outcomes by age in China, a low-income and middle-income country with a large, potentially very different patient population and with different challenges and inequalities in healthcare services than more highly resourced Western countries. Some differences between the USA and China do exist, however, in the USA, there was a twofold higher risk of death in the sub-group of women aged <50 years, while in the current study of Chinese patients the increased risk of death was observed among older patients as well, up to 70 years of age. The reasons for this international difference are unknown and worthy of further investigation. Based on the current data, and on our knowledge of gender differences in coronary heart disease, this pattern of mortality may be due to differences in healthcare delivery and access, as well as differences in disease presentation and management. Further research is needed to investigate these potential mechanisms.

Figure 2 Unadjusted risk of in-hospital mortality comparing women with men according to age (2001, 2006 and 2011). The interaction among gender, age and year was not statistically significant (p=0.38).

Figure 3 Unadjusted and adjusted risk of in-hospital mortality comparing women with men by age. In the unadjusted data (left panel), the interaction between gender and age was statistically significant (p=0.0009). After adjustment for differences in patient characteristics, hospital characteristics and year of discharge (right panel), the interaction between gender and age remained statistically significant (p=0.0012).
Coronary artery disease

disease, there are several potential explanations for the higher risk of mortality in younger women compared with similarly aged men.

Cardiovascular risk factors and co-morbidities have been considered as important contributors to gender-related mortality differences in younger patients. We speculated that, in our study, a higher burden of cardiovascular risk, such as diabetes, hypertension and chronic renal insufficiency, in younger women could contribute to the higher risk in mortality in this group. Women who develop atherosclerosis at a young age or in middle age may represent a distinct phenotype, whereby cardiovascular risk factors outweigh the protective effects of oestrogen and portend a higher risk of premature cardiovascular events and adverse outcomes following these events. In addition to considering the higher prevalence of these risk factors in younger women than their male peers, as well as their association with prognosis after AMI, moreover, in the INTERHEART study, such risk factors as diabetes and hypertension were more strongly associated with the development of myocardial infarction in women than in men, as well as in younger women (<60 years) compared with older (≥60 years) women. As such, several strategies, including prevention and the early identification and aggressive management of risk factors before the event, may be a target for future efforts to reduce the excess risk of mortality following STEMI among younger women, especially in China, a developing country with rapidly increasing cardiovascular risk factor burdens.

Other possible explanations for the poor prognosis observed among younger women include a lack of awareness of symptoms, under-recognition at presentation and lower application of evidence-based medication and timely reperfusion therapy. In our study, women aged <60 years had a longer time from symptom onset to admission compared with other age groups, which may explain the less frequent use of early reperfusion and, ultimately, the higher risk of mortality in this age group. Delayed hospital presentation in younger women may be due to atypical symptom onset of AMI, which can also result in delayed detection of the condition after the patients arrive at hospital. In addition, less use of evidence-based therapies at admission may contribute to the higher mortality in younger women. Of note, the US studies have found that the gender difference in evidence-based treatment did not adequately account for the observed mortality disparity. However, in developing countries, addressing the aforementioned disparities in disease awareness, recognition and timely administration of evidence-based therapies could lead to meaningful improvements in the care of young women with AMI and should be a target of future interventions.

In our study, however, adjustment for differences in co-morbidities, clinical characteristics at admission, treatments, and hospital characteristics did not eliminate the gender–age interaction, suggesting the contribution of alternative mechanisms to this observation. Other clinical factors not measured in this study, such as door-to-balloon time and coronary angiographic characteristics, may be involved. Moreover, biological factors not typically measured, including plaque type, clotting mechanisms, coagulability states, hormonal status, and coronary spasm, may also be involved. Alternatively, in the specific context of China, the influence of socioeconomic, cultural, educational and psychological factors may be potential contributors, especially in rural areas. Investigation into these and other factors may have important implications for how we educate patients and physicians, as well as how we assess the risk and evaluate treatment strategies for younger women with AMI.

Limitations

Our findings should be interpreted within the context of several potential limitations. First, we lacked data on some important clinical variables, such as door-to-balloon time, coronary angiographic characteristics and other potential unmeasured factors, which may have influenced management. However, we were able to adjust for several potential confounders, including cardiovascular risk, severity of illness on presentation and practice management. Second, based on the random sampling design, we may have had inadequate sample size to detect important differences within specific age groups. For example, the proportion of premenopausal women was relatively low, which prevented us from having an adequate sample size to investigate patients <55 years of age. Finally, we had no information on pre-hospital death and long-term health outcomes of patients with STEMI.

CONCLUSIONS

Similar to findings in the USA and other developed countries, among a Chinese population with STEMI, gender differences in early mortality were age-dependent and greatest among the younger groups <70 years of age. This pattern persisted even after adjusting for a wide range of confounders, including patient characteristics and hospital characteristics. Further research is required to enhance the understanding and development of interventions to improve the outcomes of younger women, especially in low-income and middle-income countries undergoing epidemiological transition like China.

Key messages

What is already known on this subject?

In studies from high-income areas such as the USA, Canada and Europe, gender differences in mortality following acute myocardial infarction (AMI) vary by age, with a higher risk of death observed in younger women compared with their male counterparts.

What might this study add?

In China, a low-income and middle-income country with a diverse population and healthcare system, we also observed significantly higher in-hospital mortality among younger women compared with men, following hospitalisation for ST-Segment Elevation Myocardial Infarction (STEMI). This pattern persisted after adjusting for a wide range of confounders, including patient- and hospital-level characteristics, and did not vary over time or across rural/urban areas. The gender differences were greatest in the younger groups <70 years of age.

How might this impact on clinical practice?

These findings indicate that the higher risk of death among younger women following AMI is a global health problem, found in high-income countries and in developing nations such as China. The findings identify young women as a vulnerable group for in-hospital mortality after STEMI and underscore the need for interventions to address this disparity.
Cardiovascular Diseases.

The Central Ethics Committee of the China National Center for Heart, Lung, and Blood Institute.

Commission of China. Professor Krumholz is supported by grant U01 HL105270-05 from XL. All authors interpreted data and approved the first draft of the article, with further contributions from RPD, ESS, and Wenchi Guan. We appreciate the advice by Yongfei Wang, Zhenqiu Lin, Shuxia Jiamin Liu, Wuhanbilige Hundei, Haibo Zhang, Lijuan Zhan, Lihua Zhang, Xue Du and Wenchui Guan. We appreciate the multiple contributions made by study teams at the China Oxford Centre for International Health Research and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation in the realms of study design and operations, particularly the data collection by Yi Pi, Jiamin Liu, Wuhanbilige Hundei, Haibo Zhang, Lijuan Zhan, Lihua Zhang, Xue Du and Wenchui Guan. We appreciate the advice by Yongfei Wang, Zhenqiu Lin, Shuxia Li and Haibo Zhang.

Contributors HMK and Li conceived the China PEACE study and take responsibility for all aspects of it. JL, XL, FAM, JAS, HMK and LJ designed the study. XZ wrote the first draft of the article, with further contributions from RPD, ESS, FAM, JAS, KN, XL, JL, SW, HMK and LJ. SH did statistical analysis, with support from XL. All authors interpreted data and approved the final version of the article.

Funding This project was partly supported by the Research Special Fund for Public Welfare Industry of Health (201202025) from National Health and Family Planning Commission of China. Professor Krumholz is supported by grant U01 HL105270-05 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute.

Competing interests None.

Ethics approval The Central Ethics Committee of the China National Center for Cardiovascular Diseases.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


Age-specific gender differences in early mortality following ST-segment elevation myocardial infarction in China

Xin Zheng, Rachel P Dreyer, Shuang Hu, Erica S Spatz, Frederick A Masoudi, John A Spertus, Khurram Nasir, Xi Li, Jing Li, Sisi Wang, Harlan M Krumholz and Lixin Jiang

Heart published online December 15, 2014

Updated information and services can be found at:
http://heart.bmj.com/content/early/2014/12/15/heartjnl-2014-306456

These include:

Supplementary Material
Supplementary material can be found at:
http://heart.bmj.com/content/suppl/2014/12/15/heartjnl-2014-306456.DC1

References
This article cites 27 articles, 5 of which you can access for free at:
http://heart.bmj.com/content/early/2014/12/15/heartjnl-2014-306456#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (236)
Epidemiology (3752)
Acute coronary syndromes (2742)
Drugs: cardiovascular system (8842)

Notes
To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/